Intermittent vismodegib therapy in advanced BCC: Experience in an oncology reference center in Colombia
DOI:
https://doi.org/10.35509/01239015.859Keywords:
vismodegib, Hedgehog pathway inhibitor, basal cell carcinomaAbstract
Objective: To describe the clinical outcomes of patients with advanced basal cell carcinoma (BCC) treated with vismodegib in the Department of Dermatology-Oncology of the Instituto Nacional de Cancerología (INC), Bogotá, Colombia, between June 2014 and January 2020.
Methods: A retrospective observational case series study was conducted. The clinical, histopathological, treatment, and clinical response variables are presented in tables and described using absolute and relative frequency measures for qualitative variables and central tendency measures for quantitative variables.
Results: A total of 55 patients with a median of 9 cycles of vismodegib and 18 months of treatment duration were analyzed; 34 patients (61.8%) discontinued treatment, 21.8% due to disease progression. An objective clinical response was observed in 80% of patients, with complete response in 41.8% and partial response in 38.2%. Adverse effects were reported in 53 patients (96.4%); the most frequent types were cramps in 76.3%, dysgeusia in 63.6%, and weight loss in 54.5%. These adverse effects were predominantly grade 1 and 2, obtaining grade 3 in 8.4% of the cases and no cases in grade 4.
Conclusion: This case series of patients with BCC who received an intermittent dosing schedule with vismodegib evidenced objective response rates comparable to those reported in prospective studies with a favourable safety profile and lower rates of high-grade adverse effects and treatment suspension due to this reason.
Author Biographies
Leonardo Pulido, Unidad Funcional Dermatología, Instituto Nacional de Cancerología, Bogotá, D.C., Colombia.
1. Unidad Funcional Dermatología, Instituto Nacional de Cancerología, Bogotá, D.C., Colombia.
María Ospina, Unidad Funcional Dermatología, Instituto Nacional de Cancerología, Bogotá, D.C., Colombia.
1. Unidad Funcional Dermatología, Instituto Nacional de Cancerología, Bogotá, D.C., Colombia.
Ángel O. Jaimes, Unidad Funcional Dermatología, Instituto Nacional de Cancerología, Bogotá, D.C., Colombia.
1. Unidad Funcional Dermatología, Instituto Nacional de Cancerología, Bogotá, D.C., Colombia.
José Carreño, Grupo de Investigación Clínica y Epidemiológica del Cáncer, Instituto Nacional de Cancerología, Bogotá, D.C., Colombia.
2. Grupo de Investigación Clínica y Epidemiológica del Cáncer, Instituto Nacional de Cancerología, Bogotá, D.C., Colombia.
References
Kim DP, Kus KJB, Ruiz E. Basal cell carcinoma review. Hematol Oncol Clin North Am. 2019;33(1):13–24. https://doi.org/10.1016/j.hoc.2018.09.004
Verkouteren JAC, Ramdas KHR, Wakkee M, Nijsten T. Epidemiology of basal cell carcinoma: Scholarly review. Br J Dermatol. 2017;177(2):359–72. https://doi.org/10.1111/bjd.15321
Sánchez G, Nova J, de la Hoz F. Factores de riesgo de carcinoma basocelular. Un estudio del Centro Nacional de Dermatología de Colombia. Actas Dermosifiliogr. 2012;103(4):294–300. https://doi.org/10.1016/j.ad.2011.07.012
Mohan S V., Chang ALS. Advanced basal cell carcinoma: epidemiology and therapeutic innovations. Curr Dermatol Rep. 2014;3(1):40–5. https://doi.org/10.1007/s13671-014-0069-y
Cameron MC, Lee E, Hibler BP, Barker CA, Mori S, Cordova M, et al. Basal cell carcinoma: Epidemiology; pathophysiology; clinical and histological subtypes; and disease associations. J Am Acad Dermatol. 2019;80(2):303–17.https://doi.org/10.1016/j.jaad.2018.03.060
Epstein EH. Basal cell carcinomas: Attack of the hedgehog. Nat Rev Cancer. 2008;8(10):743–54. https://doi.org/10.1038/nrc2503
Sekulic A, Migden MR, Oro AE, Dirix L, Lewis KD, Hainsworth JD, et al. Efficacy and safety of vismodegib in advanced basalcell carcinoma. N Engl J Med. 2012;366(23):2171–9. https://doi.org/10.1056/NEJMoa1113713
Sekulic A, Migden MR, Lewis K, Hainsworth JD, Solomon JA, Yoo S, et al. Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC. J Am Acad Dermatol. 2015;72(6):1021-1026.e8. https://doi.org/10.1016/j.jaad.2015.03.021
Basset-Séguin N, Hauschild A, Kunstfeld R, Grob J, Dréno B, Mortier L, et al. Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial. Eur J Cancer. 2017;86(2017):334–48. https://doi.org/10.1016/j.ejca.2017.08.022
Sofen H, Gross KG, Goldberg LH, Sharata H, Hamilton TK, Egbert B, et al. A phase II, multicenter, open-label, 3-cohort trial evaluating the efficacy and safety of vismodegib in operable basal cell carcinoma. J Am Acad Dermatol [Internet]. 2015;73(1):99-105.e1. https://doi.org/10.1016/j.jaad.2015.03.013
Tronconi MC, Solferino A, Giordano L, Borroni R, Mancini L, Santoro A. Tailored toxicity-driven administration of vismodegib in patients with multiple or locally advanced basal cell carcinoma: A pilot analysis. Front Oncol. 2020;10:1-6. https://doi.org/10.3389/fonc.2020.563404
Chanu P, Musib L, Wang X, Cheeti S, Girish S, Bruno R, et al. Vismodegib efficacy in advanced basal cell carcinoma maintained with 8-week dose interruptions: A model-based evaluation. J Invest Dermatol. 2021;141(4):930–3. https://doi.org/10.1016/j.jid.2020.07.036
Yang X, Dinehart SM. Intermittent vismodegib therapy in basal cell nevus syndrome. JAMA Dermatology. 2016;152(2):223–4. https://doi.org/10.1001/jamadermatol.2015.3210
Gutzmer R, Solomon JA. Hedgehog pathway inhibition for the treatment of basal cell carcinoma. Target Oncol. 2019;14(3):253–67. https://doi.org/10.1007/s11523-019-00648-2
Zhang H, Sun Z, Liu Z, Song C. Overcoming the emerging drug resistance of smoothened: An overview of small molecule SMO antagonists with antiresistance activity. Future Med Chem. 2018;10(24):2855–75. https://doi.org/10.4155/fmc-2018-0200
Ojeda-Rodríguez K, Contreras-Mejía F, Pulido-Prieto L, López-Daza D. Experiencia en el tratamiento del carcinoma basocelular localmente avanzado o metastásico con vismodegib en el Instituto Nacional de Cancerología entre los años 2014 y 2015. Rev Argentina Dermatología. 2020;101(2):1–10. Disponible en: http://rad-online.org.ar/wp-content/uploads/2020/10/Experiencia-en-el-tratamiento-del-carcinoma-basocelularlocalmente-avanzado-o-metast%C3%A1sico-con-Vismodegiben-el-instituto-nacional-de-cancerolog%C3%ADa-entre-losa%C3%B1os-2014-y-2015.-1.pdf
Sekulic A, Migden MR, Basset-Seguin N, Garbe C, Gesierich A, Lao CD, et al. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: Final update of the pivotal ERIVANCE BCC study. BMC Cancer. 2017;17(1):1–10. https://doi.org/10.1186/s12885-017-3286-5
Chang ALS, Solomon JA, Hainsworth JD, Goldberg L, McKenna E, Day BM, et al. Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib. J Am Acad Dermatol. 2014;70(1):60–9. https://doi.org/10.1016/j.jaad.2013.09.012
Frampton JE, Basset-Séguin N. Vismodegib: A review in advanced basal cell carcinoma. Drugs. 2018;78(11):1145–56. https://doi.org/10.1007/s40265-018-0948-9
Lacouture M, Guillen J, Kudchadkar R, Rogers G, Olencki T, Tang JY, et al. 3341 The RegiSONIC disease registry study: Safety and effectiveness of vismodegib or surgery as primary treatment in patients with locally advanced basal cell carcinoma. Eur J Cancer. 2015;51:S679–80. https://doi.org/10.1016/S0959-8049(16)31859-7
Dréno B, Kunstfeld R, Hauschild A, Fosko S, Zloty D, Labeille B, et al. Two intermittent vismodegib dosing regimens in patients with multiple basal-cell carcinomas (MIKIE): A randomised, regimen-controlled, double-blind, phase 2 trial. Lancet Oncol. 2017;18(3):404–12. https://doi.org/10.1016/S1470-2045(17)30072-4
Basset-Seguin N, Dupuy A, Saiag P, Dalac-Rat S, Guillot B, Routier E, et al. VISMONEO - a phase II study assessing vismodegib in the neoadjuvant treatment of locally advanced basal cell carcinoma - Patients characteristics. Ann Oncol. 2016;27(Suppl6):vi399. https://doi.org/10.1093/annonc/mdw379.49
Block AM, Alite F, Diaz AZ, Borrowdale RW, Clark JI, Choi M. Combination trimodality therapy using vismodegib for basal cell carcinoma of the face. Case Rep Oncol Med. 2015;2015:1–6. https://doi.org/10.1155/2015/827608
Gathings RM, Orscheln CS, Huang WW. Compassionate use of vismodegib and adjuvant radiotherapy in the treatment of multiple locally advanced and inoperable basal cell carcinomas and squamous cell carcinomas of the skin. J Am Acad Dermatol. 2014;70(4):e88–9. https://doi.org/10.1016/j.jaad.2013.11.032
Bertrand N, Guerreschi P, Basset-Seguin N, Saiag P, Dupuy A, Dalac-Rat S, et al. Vismodegib in neoadjuvant treatment of locally advanced basal cell carcinoma: First results of a multicenter, open-label, phase 2 trial (VISMONEO study): Neoadjuvant vismodegib in locally advanced basal cell carcinoma. EClinicalMedicine. 2021;35:1-8. https://doi.org/10.1016/j.eclinm.2021.100844
Venkatesulu BP, Hsieh CC. Proceedings of the American Radium Society®’s 103rd Annual Meeting. American Journal of Clinical Oncology. 2021;44(10):S1-S145. https://doi.org/10.1097/COC.0000000000000862
Scalvenzi M, Cappello M, Costa C, Fabbrocini G, Luciano M, Villani A. Low-Dose vismodegib as maintenance therapy after locally advanced basal cell carcinoma complete remission: High efficacy with minimal toxicity. Dermatol Ther (Heidelb). 2020;10(3):465–8. https://doi.org/10.1007/s13555-020-00371-1
How to Cite
Downloads
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Revista Colombiana de Cancerología
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Todos los derechos reservados.
